DOV-102,677
id:
dov-102-677-196-18786377
title:
DOV-102,677
text:
DOV-102,677 is a psychoactive drug being developed by Merck and is currently in clinical trials. It is a triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It is the (−)-enantiomer of DOV-216,303, and its (+)-enantiomer is DOV-21,947 (amitifadine). Instead of being developed for depression, DOV-102,677 is being developed for the treatment of alcoholism. IC50 values for the SERT, NET and DAT are 129 nM, 103 nM, and 133 nM. DOV-102,677 increased extra
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/DOV-102,677
date created:
date modified:
2024-01-16T04:32:00Z
main entity:
{"identifier":"Q5205903","url":"https://www.wikidata.org/entity/Q5205903"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/9/95/DOV-102677.svg","width":512,"height":469}
fields total:
13
integrity:
15